ABSCI CORP
ABSINASDAQTrading Snapshot
- Day Range
- $10.43 – $11.89
- 52-Week Range
- $2.24 – $12.06
- Volume (shares)
- 5,805,907
- Avg Volume (shares)
- —
- Shares Outstanding
- 171.6M
- Next Earnings
- 2026-11-12
Fundamentals Snapshot
- Annual Revenue
- $3M
- Last Q Revenue
- $318,000
- P/E Ratio
- -13.2
- P/S Ratio
- 1162.0x
- EPS (TTM)
- $-0.77
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +31.0%
ABSCI CORP
ABSI
StockOtter · stockotter.spaceAbout ABSCI CORP
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Absci to Participate in Upcoming Investor Conferences
VANCOUVER, Wash. and NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announc
Absci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026
VANCOUVER, Wash. and NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announc
Critical Contrast: Absci (NASDAQ:ABSI) and Black Diamond Therapeutics (NASDAQ:BDTX)
Black Diamond Therapeutics (NASDAQ: BDTX - Get Free Report) and Absci (NASDAQ: ABSI - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses bas
Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis
Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial in mid-2027 VANCOUVER
Absci (NASDAQ:ABSI) vs. Silence Therapeutics (NASDAQ:SLN) Head to Head Contrast
Silence Therapeutics (NASDAQ: SLN - Get Free Report) and Absci (NASDAQ: ABSI - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the stre
Contrasting Absci (NASDAQ:ABSI) & Valneva (NASDAQ:VALN)
Valneva (NASDAQ: VALN - Get Free Report) and Absci (NASDAQ: ABSI - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of t